183 results on '"Kerbel, Robert S."'
Search Results
2. Supplementary Figure Legends 1-2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
3. Data from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
4. Supplementary Table 3 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
5. Supplementary Figure 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
6. Supplementary Video 3 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
7. Data from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
8. Supplementary Figure Legends 1-2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
9. Supplementary Tables S1-S4 from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
10. Data from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
11. Supplementary materials and methods and legends for Supplementary Figures and Tables from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
12. Supplementary Tables S1-S4 from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
13. Supplementary Video 4 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
14. Supplementary Table 3 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
15. Supplementary Methods and Materials; Supplementary Figures S1-S4 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
16. Supplementary Figures from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
17. Data from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
18. Supplementary materials and methods and legends for Supplementary Figures and Tables from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
19. Data from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
20. Supplementary Methods and Materials; Supplementary Figures S1-S4 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
21. Supplementary Video 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
22. Supplementary Table 1 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
23. Supplementary Table 2 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
24. Supplementary Figure 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
25. Supplementary Video 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
26. Supplementary Video 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
27. Supplementary Video 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
28. Supplementary Figures from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
29. Data from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
30. Supplementary Video 4 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
31. Supplementary Table 1 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
32. Supplementary Video 3 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
33. Supplementary Table 2 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
34. Supplementary Figure 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
35. Supplementary Figure 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
36. Supplementary Figure S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
37. Supplementary Figure Legends from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
38. Supplementary Table S3 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
39. Supplemental Figures S1-S6 from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
40. Data from Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
41. Supplemental figures 1-3 from Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy
42. Data from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
43. CCR Translation for the Article from Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts
44. Supplementary Figure S1 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
45. Supplementary Table S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
46. Supplemental Figures 1-5 and Methods from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
47. Supplementary Figure S4 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
48. Supplemental Figures S1-S6 from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
49. Supplementary Table S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
50. Supplementary Figure S3 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.